Increasing anthrax incidence is fueling the Cyfendus Market 2026

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Cyfendus Market At The End Of The 2026–2030 Forecast Period?

Growth in the past was primarily driven by initiatives for bioterrorism preparedness, previous incidents of anthrax exposure, government-backed vaccine programs, the evolution of adjuvanted vaccines, and military immunization requirements.

Anticipated growth during the forecast period is projected to stem from escalated investments in biodefense, the broadening of emergency response structures, augmented financial allocations for public health, an upgraded capacity for vaccine production, and fortified global security partnerships.

Significant trends expected in the upcoming period encompass an intensified focus on vaccines for biodefense purposes, the extension of post-exposure prophylaxis initiatives, the accumulation of anthrax vaccine reserves by governments, a growing convergence of vaccines with antibiotic treatments, and the reinforcement of national emergency readiness.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20030&type=smp

Which Market Drivers Are Supporting The Expansion Of The Cyfendus Market?

The projected expansion of the cyfendus market is linked to the increasing occurrence of anthrax. Anthrax incidence quantifies the reported cases of the disease in a particular population or region over a set timeframe, serving as an indicator of its prevalence and assisting public health bodies in assessing risks and formulating preventative strategies. The increase in anthrax cases stems from heightened contact between humans and animals in affected areas, environmental elements such as spore release from disrupted soils, and insufficient vaccination rates among livestock. Cyfendus is crucial for anthrax as it offers post-exposure protection by prompting the immune system to generate antibodies against the anthrax bacteria when administered with antibiotics. For example, the World Health Organization (WHO), an intergovernmental body based in Switzerland, reported in December 2023 that Zambia had 684 suspected human anthrax cases by November 2023, with four deaths, resulting in a Case Fatality Ratio (CFR) of 0.6%. These infections affected 44 out of the country’s 116 districts; Sinazongwe district was most severely impacted, recording 287 cases (42% of the total) and two deaths (50% of all fatalities). Consequently, the rising occurrence of anthrax is a key factor propelling the expansion of the cyfendus market.

What Segment Types Make Up The Cyfendus Market?

The cyfendus market covered in this report is segmented –

1) By Route Of Administration: Parenteral, Oral

2) By Clinical Indications: Pre-Exposure Prophylaxis, Post-Exposure Prophylaxis, Special Populations

3) By Distribution Channel: Hospital Pharmacies, Outpatient Clinics, Specialty Pharmacies

Which Market Trends Are Creating New Opportunities In The Cyfendus Market?

Major companies operating within the cyfendus market are concentrating on developing advanced solutions, such as post-exposure prophylactic vaccines, to bolster immune protection, mitigate infection risk, and enhance responsiveness in high-risk environments. These post-exposure prophylactic vaccines are medical preparations specifically designed to stimulate the immune system to produce antibodies against Bacillus anthracis, either before or after exposure, thereby preventing the development of anthrax. For instance, in July 2023, Emergent BioSolutions Inc., a US-based biotechnology company, announced U.S. Food and Drug Administration (FDA) approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted). The CYFENDUS vaccine is indicated for post-exposure prophylaxis in individuals aged 18 to 65 following suspected or confirmed exposure to Bacillus anthracis, when utilized alongside recommended antibiotics. Formulated with Anthrax Vaccine Adsorbed (AVA) and an additional adjuvant, CYFENDUS has demonstrated protective immune responses in animal models of inhalational anthrax when administered in two doses over 14 days, a critical aspect for managing large-scale public health emergencies involving anthrax.

Who Are The Key Players Driving Competition In The Cyfendus Market?

Major companies operating in the cyfendus market are Emergent BioSolutions Inc.

Read the full cyfendus market report here:

https://www.thebusinessresearchcompany.com/report/cyfendus-global-market-report

How Is The Cyfendus Market Distributed Across Key Geographic Regions?

North America was the largest region in the cyfendus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cyfendus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cyfendus Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20030&type=smp

Browse Through More Reports Similar to the Global Cyfendus Market 2026, By The Business Research Company

Biodefense Market Report 2026

https://www.thebusinessresearchcompany.com/report/biodefense-global-market-report

Interstitial Cystitis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/interstitial-cystitis-drugs-global-market-report

Veterinary Pharmaceuticals Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-pharmaceuticals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795